Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparative time-kill study of doxycycline, tigecycline, cefazolin and vancomycin against several clones of Staphylococcus aureus.

Current clinical pharmacology - 1 Nov 2013

Herrera Melina, Mobilia Liliana, Posse Graciela, Limansky Adriana, Ballerini Viviana, Bantar Carlos

Abstract excerpt

BACKGROUND: We present herein, a comparative study assessing the bactericidal kinetics of tigecycline, doxycycline, cefazolin and vancomycin against several methicllin-susceptible (MSSA) and -resistant (MRSA) Staphylococcus aureus isolates recovered from patients of 24 different cities in Argentina. METHODS: After genotypic characterization, 20 strains (10 MRSA and 10 MSSA) were selected for time-kill studies....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Argentina
Share to Doxycycline

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Methicillin-Resistant Staphylococcus aureus

Share to Minocycline

Share to Staphylococcal Infections

Share to Staphylococcus aureus

Share to Tigecycline

Share to Vancomycin

Source

Identifiers

PMID: 23590512
DOI: 10.2174/15748847113089990063

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparative time-kill study of doxycycline, tigecycline, cefazolin and vancomycin against several clones of Staphylococcus aureus.PMID 23590512Read ↗

In vitro antimicrobial activity and resistance mechanisms of the new generation tetracycline agents, eravacycline, omadacycline, and tigecycline against clinical Staphylococcus aureus isolatesSemantic proximity Read ↗

Changes in Staphylococcus aureus susceptibility across Latin America between 2004 and 2010Semantic proximity Read ↗

Antibacterial Efficacy of Eravacycline <i>In Vivo</i> against Gram-Positive and Gram-Negative OrganismsSemantic proximity Read ↗

In vitro selection of Staphylococcus aureus mutants resistant to tigecycline with intermediate susceptibility to vancomycin.Semantic proximity Read ↗

Tigecycline - how powerful is it in the fight against antibiotic-resistant bacteria?Semantic proximity Read ↗

Molecular characterization of methicillin-resistantStaphylococcus aureusresistant to tigecycline and daptomycin isolated in a hospital in BrazilSemantic proximity Read ↗

Characterization of baseline methicillin-resistant Staphylococcus aureus isolates recovered from phase IV clinical trial for linezolid.Semantic proximity Read ↗

Zyvox(R) Annual Appraisal of Potency and Spectrum (ZAAPS) Program: report of linezolid activity over 9 years (2004-12)Semantic proximity Read ↗

Studies on time-kill kinetics of different classes of antibiotics against veterinary pathogenic bacteria including Pasteurella, Actinobacillus and Escherichia coli.Semantic proximity Read ↗

In Vitro Activities of Ceftobiprole, Tigecycline, Daptomycin, and 19 Other Antimicrobials against Methicillin-Resistant Staphylococcus aureus Strains from a National Survey of Belgian HospitalsSemantic proximity Read ↗

Genetic changes associated with tigecycline resistance in Staphylococcus aureus in vitro-selected mutants belonging to different lineages.Semantic proximity Read ↗

Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.